Prologue is designing powerful new medicines by unlocking the viral proteome. The company’s state-of-the-art DELVE™ Platform systematically identifies and evaluates viral proteins and their unique features for their potential to precisely regulate human physiology. By co-opting viral evolution, Prologue is expanding the functional boundaries of proteins encoded by the human genome to create new programmable medicines. Prologue was founded by Flagship Pioneering in 2021.
Company Details
- Employees
- 24
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.prologuemedicines.com
Prologue Medicines Questions
Prologue Medicines's website is http://www.prologuemedicines.com
Prologue Medicines's LinkedIn profile is https://www.linkedin.com/company/prologue-medicines
Prologue Medicines has
24 employees.
View email and phone details for 24
employees at Prologue Medicines.
Prologue Medicines's industry is
Biotechnology Research
Prologue Medicines's top competitors are
Sana Biotechnology, Inc.,
Tessera Therapeutics,
Apriori Bio,
Ampersand Biomedicines,
Profound Therapeutics,
Flagship Pioneering,
Metaphore Biotechnologies,
Montai Therapeutics,
Alltrna,
Mirai Bio.
Prologue Medicines's categories are Biotechnology Research
